Immunocore (IMCR) director granted 27,492 options at $28.52 strike
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Immunocore Holdings plc director Peter John Ratcliffe received a new stock option grant. On May 27, 2026, he was granted options over 27,492 ordinary shares at an exercise price of $28.52 per share, with no cash paid for the grant itself.
The options expire on May 26, 2036 and represent his entire reported option position of 27,492 options following this transaction. According to the terms, the award will vest at the earlier of May 27, 2027 or the day immediately prior to Immunocore’s next annual general meeting, provided he continues in service through the vesting date.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Ratcliffe Peter John
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Share Option (Right to Buy) | 27,492 | $0.00 | -- |
Holdings After Transaction:
Share Option (Right to Buy) — 27,492 shares (Direct, null)
Footnotes (1)
- [object Object]
Key Figures
Options granted: 27,492 options
Exercise price: $28.52/share
Expiration date: May 26, 2036
+2 more
5 metrics
Options granted
27,492 options
Grant of share options on May 27, 2026
Exercise price
$28.52/share
Exercise price for the 27,492 options
Expiration date
May 26, 2036
Option award expiration
Post-transaction options held
27,492 options
Total options owned following the grant
Vesting latest date
May 27, 2027
Latest vesting date, subject to earlier AGM-related vesting
Key Terms
Share Option (Right to Buy), Grant, award, or other acquisition, exercise price, expiration date, +1 more
5 terms
Grant, award, or other acquisition financial
"transaction_code_description: "Grant, award, or other acquisition""
exercise price financial
"conversion_or_exercise_price: "28.5200""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: "2036-05-26T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
vesting financial
"The shares subject to the option award shall vest at the earlier of"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
What did Immunocore (IMCR) director Peter John Ratcliffe receive in this Form 4?
Peter John Ratcliffe received a grant of stock options over 27,492 Immunocore ordinary shares. The options are a compensation-related award, not an open-market share purchase, and give him the right to buy shares at a fixed exercise price of $28.52.
What are the key terms of Peter John Ratcliffe’s new Immunocore stock options?
The new award covers 27,492 options with an exercise price of $28.52 per share and an expiration date of May 26, 2036. These options were granted at no upfront cost as part of his role with Immunocore Holdings plc.
When do Peter John Ratcliffe’s Immunocore options vest according to this filing?
The options vest at the earlier of May 27, 2027 or the day immediately before Immunocore’s next annual general meeting. Vesting is conditional on Ratcliffe’s continuous service with the company through the applicable vesting date, as described in the award footnote.
How many Immunocore options does Peter John Ratcliffe hold after this Form 4 transaction?
After this transaction, Ratcliffe holds 27,492 stock options in Immunocore. This total equals the full size of the new grant, indicating the filing reports his current option position related to this award following the grant on May 27, 2026.